Results 161 to 170 of about 1,796 (202)

Case Report: A rare <i>RUNX1</i> rearrangement resulting from t(8;21)(p12;q22) in acute myeloid leukemia with plasmacytoid dendritic cell expansion. [PDF]

Front Oncol
Gong J, Liu J, Lu L, Wei J, Wu X, Zou J, Feng Y, Zhu G, Han J.   +8 more
europepmc   +1 more source

Different Presentations and Different Treatment Options in Blastic Plasmacytoid Dendritic Cell Neoplasms: A Case Series. [PDF]

Int J Hematol Oncol Stem Cell Res
Cengiz E, Aydin MS, Gunes AK, Ceran F, Dagdas S, Ozet G.   +5 more
europepmc   +1 more source

Early detection of transformation to BPDCN in a patient with MDS [PDF]

Experimental Hematology and Oncology, 2018
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression of CD56. Historically, patients with BPDCN have an unfavorable prognosis and the optimal treatment is not established due to lack of prospective ...
Naveen Pemmaraju, Marisa J Hornbaker, Shimin Hu   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Targeting CD123 in BPDCN: an emerging field

Expert Review of Hematology, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with historically poor outcomes for patients, often refractory to traditional chemotherapy. Recent research has focused on targeted therapy to improve responses and limit potential toxicity.CD123 (also known as IL-3 Rα) is a cell surface marker and ...
Nathaniel R Wilson, Naveen Pemmaraju
exaly   +3 more sources

Targeted diphtheria toxin to treat BPDCN

Blood, 2014
In this issue of Blood, Frankel et al describe a novel treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) using an engineered version of diphtheria toxin that is targeted to malignant cells via a fusion with interleukin (IL)3 (see panel A).
exaly   +4 more sources

Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Pharmacotherapy, 2022
Unique among hematologic malignancies, blastic plasmacytoid dendritic cell neoplasm (BPDCN) affects multiple compartments including bone marrow, hematologic, lymphatic, dermatologic, and central nervous systems (CNS). Treating BPDCN is challenging, historically, as patients display refractoriness to chemotherapy and absence of long-term remissions in ...
Nathaniel R Wilson, Naveen Pemmaraju
exaly   +3 more sources

Promising results with tagraxofusp in BPDCN

Lancet Oncology, The, 2019
exaly   +3 more sources

Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview

Hematology Reports, 2023
Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCNs) are a rare, highly aggressive hematological malignant neoplasm that primarily involve the skin, bone marrow, lymph nodes and even extra-nodal sites. The rarity and relative poor description of cases in the literature make it necessary to review and further studies that deeply investigate this ...
Gerardo Cazzato, Giovanni De Biasi, Anna Colagrande   +2 more
exaly   +4 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN—Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community

Current Hematologic Malignancy Reports, 2018
Engagement on social media for professional, healthcare-related communication is rapidly rising around the world. We aimed to better understand the dynamics of a rare disease Twitter hashtag community.Twitter has served as a platform for academic discussion, a method for knowledge dissemination directly from medical meetings, and a venue for patient ...
Naveen Pemmaraju, Audun Utengen, Andrew A Lane   +2 more
exaly   +4 more sources